Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
All content for CME in Minutes: Education in Dermatology is the property of Answers in CME and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies
CME in Minutes: Education in Dermatology
15 minutes 6 seconds
1 month ago
Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies
Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.
CME in Minutes: Education in Dermatology
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.